NCT02670525Active, not recruiting
Matched Targeted Therapy For High-Risk Leukemias and Myelodysplastic Syndrome
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic Syndrome
Source: ClinicalTrials.gov · Last updated 6 Aug 2026
Brief summary (registry, in English)
This research study is seeking to gain new knowledge about Recurrent, Refractory, or High Risk Leukemias in children and young adults. This study is evaluating the use of specialized testing called leukemia profiling. Once the profiling is performed, the results are evaluated by an expert panel of physicians, scientists and pharmacists. This may result in a recommendation for a specific cancer therapy or a clinical trial called matched targeted therapy (MTT). The results of the leukemia profiling and, if applicable, the MTT recommendation will be communicated to the participant's primary oncologist.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 338 (actual)
- First submitted
- 28 Jan 2016
- Start date
- 17 Aug 2016
- Primary completion date
- 16 May 2022
- Lead sponsor
- Dana-Farber Cancer Institute
- NCT number
- NCT02670525
What you commit to
- Study type: Interventional
- Participants enrolled: 338
- From 17 Aug 2016 to the primary completion date, 16 May 2022
- 15 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Insufficient leukemia specimen available for profiling from diagnosis or recurrence; or bone marrow evaluation/blood draw/other leukemia cell sample NOT planned to be obtained for clinical care; or peripheral blast percentage \<20% AND clinical blood draw not planned.
Who the study is looking for
- Birth to ≤ 30 years at study entry
- Diagnosis: Patients will be enrolled in one of the two cohorts based on diagnosis:
- Cohort 1: Relapsed/refractory leukemia
- Acute lymphoblastic leukemia (ALL), first or greater relapse
- Acute myeloid leukemia (AML), first or greater relapse
- Leukemia refractory to induction chemotherapy
- Other recurrent leukemia
- Myelodysplastic syndrome (MDS), first or greater relapse, or refractory to initial therapy
- Cohort 2: New diagnosis
- Acute myeloid leukemia (AML), new diagnosis
- New diagnosis infant mixed-lineage leukemia (MLL)-rearranged ALL or low hypodiploid (\<40 chromosomes) ALL
- Rare leukemia- e.g., juvenile myelomonocytic leukemia (JMML), leukemia of ambiguous lineage
- Secondary leukemia
- Myelodysplastic syndrome (MDS) not eligible for stem cell transplant
- Pathologic Criteria
- Histologic confirmation of leukemia at the time of diagnosis or recurrence
- Specimen Samples
- Sufficient leukemia specimen available for profiling from diagnosis or recurrence OR bone marrow aspirate/blood draw/pheresis/other fresh sample of patient leukemia cells planned for clinical care anticipated to allow collection of minimum specimen for testing.
Age in the registry: - to 30 years · Sex: All · Does not accept healthy volunteers
Sites (15)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's Healthcare of Atlanta Coordinator of this site? Confirm its status | Atlanta | United States | Unknown status |
| Children's Hospital Colorado Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
| Johns Hopkins Hospital Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Roswell Park Comprehensive Cancer Center Coordinator of this site? Confirm its status | Buffalo | United States | Unknown status |
| The University Of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
| Children's Hospital of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Unknown status |
| Children's Hospital's and Clinics of Minnesota Coordinator of this site? Confirm its status | Minneapolis | United States | Unknown status |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Columbia University Medical Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Children's Hospital of Philadelphia Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
| UCSF Helen Diller Family Comprehensive Cancer Center Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
| Seattle Children's Hospital Coordinator of this site? Confirm its status | Seattle | United States | Unknown status |
| Washington University at St. Louis School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Unknown status |
| The Children's Hospital at Montefiore Coordinator of this site? Confirm its status | The Bronx | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.